107 related articles for article (PubMed ID: 12764388)
1. Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera.
Silver RT
Leukemia; 2003 Jun; 17(6):1186-7. PubMed ID: 12764388
[No Abstract] [Full Text] [Related]
2. Polycythemia vera responds to imatinib mesylate.
Jones CM; Dickinson TM
Am J Med Sci; 2003 Mar; 325(3):149-52. PubMed ID: 12640290
[TBL] [Abstract][Full Text] [Related]
3. Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate.
Silver RT
Curr Hematol Rep; 2005 May; 4(3):235-7. PubMed ID: 15865878
[TBL] [Abstract][Full Text] [Related]
4. Treatment of polycythemia vera with imatinib mesylate.
Silver RT; Bourla MH; Vandris K; Fruchtman S; Spivak JL; Feldman EJ; Salvado AJ
Leuk Res; 2012 Feb; 36(2):156-62. PubMed ID: 21983176
[TBL] [Abstract][Full Text] [Related]
5. Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study.
Merx K; Fabarius A; Erben P; Griesshammer M; Reiter A; Hofmann WK; Hehlmann R; Hochhaus A; Lengfelder E
Ann Hematol; 2013 Jul; 92(7):907-15. PubMed ID: 23525684
[TBL] [Abstract][Full Text] [Related]
6. Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate.
Silver RT
Curr Hematol Malig Rep; 2007 Feb; 2(1):43-6. PubMed ID: 20425387
[TBL] [Abstract][Full Text] [Related]
7. Phase II open label trial of imatinib in polycythemia rubra vera.
Jones CM; Dickinson TM; Salvado A
Int J Hematol; 2008 Dec; 88(5):489-494. PubMed ID: 19009241
[TBL] [Abstract][Full Text] [Related]
8. Long term follow-up of Polycythemia Vera patients treated with imatinib mesylate.
Michael Jones C
Leuk Res; 2012 Jul; 36(7):815-6. PubMed ID: 22483066
[No Abstract] [Full Text] [Related]
9. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
[TBL] [Abstract][Full Text] [Related]
10. Imatinib effect on growth and signal transduction in polycythemia vera.
Gaikwad A; Verstovsek S; Yoon D; Chang KT; Manshouri T; Nussenzveig R; Cortes J; Vainchenker W; Prchal JT
Exp Hematol; 2007 Jun; 35(6):931-8. PubMed ID: 17533047
[TBL] [Abstract][Full Text] [Related]
11. Fatal hepatic necrosis following imatinib mesylate therapy.
Lin NU; Sarantopoulos S; Stone JR; Galinsky I; Stone RM; Deangelo DJ; Soiffer RJ
Blood; 2003 Nov; 102(9):3455-6. PubMed ID: 14568907
[No Abstract] [Full Text] [Related]
12. Polycythemia vera: an evidence-based examination from a nursing perspective.
Greenberg H
Crit Care Nurs Q; 2013; 36(2):228-32. PubMed ID: 23470708
[No Abstract] [Full Text] [Related]
13. Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis.
Musto P; Falcone A; Sanpaolo G; Bodenizza C; Carella AM
Leuk Res; 2004 Apr; 28(4):421-2. PubMed ID: 15109544
[No Abstract] [Full Text] [Related]
14. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate for cerebral Langerhans'-cell histiocytosis.
Montella L; Insabato L; Palmieri G
N Engl J Med; 2004 Sep; 351(10):1034-5. PubMed ID: 15342818
[No Abstract] [Full Text] [Related]
16. Imatinib mesylate in polycythemia vera.
Spivak JL; Silver RT
Blood; 2004 Apr; 103(8):3241; author reply 3241-2. PubMed ID: 15070710
[No Abstract] [Full Text] [Related]
17. [Pipobroman in the treatment of some cases of polycythemia vera].
Bignotti G; Visca U; Confalonieri C
Haematologica; 1971; 56(3):157-62. PubMed ID: 5003588
[No Abstract] [Full Text] [Related]
18. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.
Kantarjian HM; Talpaz M
Semin Oncol; 2001 Oct; 28(5 Suppl 17):9-18. PubMed ID: 11740802
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of chronic myeloid leukemia with imatinib in the accelerated stage of the disease].
Bulum J; Labar B; Mikulić M; Bogdanić V; Sertić D; Nemet D; Krecak-Gverić V; Kovacević J; Serventi-Seiwerth R; Mrsić-Davidović S; Zadro R; Boban D
Lijec Vjesn; 2003; 125(7-8):176-9. PubMed ID: 14692090
[TBL] [Abstract][Full Text] [Related]
20. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
